Literature DB >> 23681449

Genes for elite power and sprint performance: ACTN3 leads the way.

Nir Eynon1, Erik D Hanson, Alejandro Lucia, Peter J Houweling, Fleur Garton, Kathryn N North, David J Bishop.   

Abstract

The ability of skeletal muscles to produce force at a high velocity, which is crucial for success in power and sprint performance, is strongly influenced by genetics and without the appropriate genetic make-up, an individual reduces his/her chances of becoming an exceptional power or sprinter athlete. Several genetic variants (i.e. polymorphisms) have been associated with elite power and sprint performance in the last few years and the current paradigm is that elite performance is a polygenic trait, with minor contributions of each variant to the unique athletic phenotype. The purpose of this review is to summarize the specific knowledge in the field of genetics and elite power performance, and to provide some future directions for research in this field. Of the polymorphisms associated with elite power and sprint performance, the α-actinin-3 R577X polymorphism provides the most consistent results. ACTN3 is the only gene that shows a genotype and performance association across multiple cohorts of elite power athletes, and this association is strongly supported by mechanistic data from an Actn3 knockout mouse model. The angiotensin-1 converting enzyme insertion/deletion polymorphism (ACE I/D, registered single nucleotide polymorphism [rs]4646994), angiotensinogen (AGT Met235Thr rs699), skeletal adenosine monophosphate deaminase (AMPD1) Gln(Q)12Ter(X) [also termed C34T, rs17602729], interleukin-6 (IL-6 -174 G/C, rs1800795), endothelial nitric oxide synthase 3 (NOS3 -786 T/C, rs2070744; and Glu298Asp, rs1799983), peroxisome proliferator-activated receptor-α (PPARA Intron 7 G/C, rs4253778), and mitochondrial uncoupling protein 2 (UCP2 Ala55Val, rs660339) polymorphisms have also been associated with elite power performance, but the findings are less consistent. In general, research into the genetics of athletic performance is limited by a small sample size in individual studies and the heterogeneity of study samples, often including athletes from multiple-difference sporting disciplines. In the future, large, homogeneous, strictly defined elite power athlete cohorts need to be established though multinational collaboration, so that meaningful genome-wide association studies can be performed. Such an approach would provide unbiased identification of potential genes that influence elite athletic performance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681449     DOI: 10.1007/s40279-013-0059-4

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  121 in total

1.  The ACTN3 gene in elite Greek track and field athletes.

Authors:  I D Papadimitriou; C Papadopoulos; A Kouvatsi; C Triantaphyllidis
Journal:  Int J Sports Med       Date:  2007-09-18       Impact factor: 3.118

2.  The ACE I/D polymorphism in elite Greek track and field athletes.

Authors:  I D Papadimitriou; C Papadopoulos; A Kouvatsi; C Triantaphyllidis
Journal:  J Sports Med Phys Fitness       Date:  2009-12       Impact factor: 1.637

3.  Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.

Authors:  C F Terry; V Loukaci; F R Green
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

4.  A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese.

Authors:  M Yoshimura; H Yasue; M Nakayama; Y Shimasaki; H Sumida; S Sugiyama; K Kugiyama; H Ogawa; Y Ogawa; Y Saito; Y Miyamoto; K Nakao
Journal:  Hum Genet       Date:  1998-07       Impact factor: 4.132

5.  Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity.

Authors:  X L Wang; A S Sim; M X Wang; G A Murrell; B Trudinger; J Wang
Journal:  FEBS Lett       Date:  2000-04-07       Impact factor: 4.124

6.  Association of the ACTN3 R577X polymorphism with power athlete status in Russians.

Authors:  Anastasiya M Druzhevskaya; Ildus I Ahmetov; Irina V Astratenkova; Viktor A Rogozkin
Journal:  Eur J Appl Physiol       Date:  2008-05-10       Impact factor: 3.078

7.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle.

Authors:  B Zhang; H Tanaka; N Shono; S Miura; A Kiyonaga; M Shindo; K Saku
Journal:  Clin Genet       Date:  2003-02       Impact factor: 4.438

9.  ACTN3 R577X polymorphism and Israeli top-level athletes.

Authors:  N Eynon; J A Duarte; J Oliveira; M Sagiv; C Yamin; Y Meckel; M Sagiv; E Goldhammer
Journal:  Int J Sports Med       Date:  2009-06-18       Impact factor: 3.118

10.  ACTN3 (R577X) genotype is associated with fiber type distribution.

Authors:  Barbara Vincent; Katrien De Bock; Monique Ramaekers; Els Van den Eede; Marc Van Leemputte; Peter Hespel; Martine A Thomis
Journal:  Physiol Genomics       Date:  2007-09-11       Impact factor: 3.107

View more
  55 in total

Review 1.  Sprint Running Performance Monitoring: Methodological and Practical Considerations.

Authors:  Thomas Haugen; Martin Buchheit
Journal:  Sports Med       Date:  2016-05       Impact factor: 11.136

2.  The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance.

Authors:  Fleur C Garton; Peter J Houweling; Damjan Vukcevic; Lyra R Meehan; Fiona X Z Lee; Monkol Lek; Kelly N Roeszler; Marshall W Hogarth; Chrystal F Tiong; Diana Zannino; Nan Yang; Stephen Leslie; Paul Gregorevic; Stewart I Head; Jane T Seto; Kathryn N North
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

3.  ACTN3 genotype influences exercise-induced muscle damage during a marathon competition.

Authors:  Juan Del Coso; Marjorie Valero; Juan José Salinero; Beatriz Lara; Germán Díaz; César Gallo-Salazar; Diana Ruiz-Vicente; Francisco Areces; Carlos Puente; Juan Carlos Carril; Ramón Cacabelos
Journal:  Eur J Appl Physiol       Date:  2017-02-02       Impact factor: 3.078

4.  History-dependent force, angular velocity and muscular endurance in ACTN3 genotypes.

Authors:  Siacia Broos; Marc Van Leemputte; Louise Deldicque; Martine A Thomis
Journal:  Eur J Appl Physiol       Date:  2015-03-12       Impact factor: 3.078

Review 5.  Concurrent exercise training: do opposites distract?

Authors:  Vernon G Coffey; John A Hawley
Journal:  J Physiol       Date:  2016-10-09       Impact factor: 5.182

6.  Genetics and the Elite Athlete: Our Understanding in 2020.

Authors:  Rakesh John; Mandeep Singh Dhillon; Sidak Dhillon
Journal:  Indian J Orthop       Date:  2020-03-11       Impact factor: 1.251

7.  Analysis of the ACTN3 heterozygous genotype suggests that α-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion.

Authors:  Marshall W Hogarth; Fleur C Garton; Peter J Houweling; Taru Tukiainen; Monkol Lek; Daniel G Macarthur; Jane T Seto; Kate G R Quinlan; Nan Yang; Stewart I Head; Kathryn N North
Journal:  Hum Mol Genet       Date:  2015-12-17       Impact factor: 6.150

Review 8.  More than a 'speed gene': ACTN3 R577X genotype, trainability, muscle damage, and the risk for injuries.

Authors:  Juan Del Coso; Danielle Hiam; Peter Houweling; Laura M Pérez; Nir Eynon; Alejandro Lucía
Journal:  Eur J Appl Physiol       Date:  2018-10-16       Impact factor: 3.078

Review 9.  Genetic and epigenetic sex-specific adaptations to endurance exercise.

Authors:  Shanie Landen; Sarah Voisin; Jeffrey M Craig; Sean L McGee; Séverine Lamon; Nir Eynon
Journal:  Epigenetics       Date:  2019-04-13       Impact factor: 4.528

10.  Genetic test for the personalization of sport training.

Authors:  Zakira Naureen; Marco Perrone; Stefano Paolacci; Paolo Enrico Maltese; Kristjana Dhuli; Danjela Kurti; Astrit Dautaj; Roberta Miotto; Arianna Casadei; Bernard Fioretti; Tommaso Beccari; Francesco Romeo; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.